This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the ability to achieve the expected benefits from the generic sourcing venture with CVS Health; the frequency or rate of pharmaceutical price appreciation or deflation and the timing of generic and branded pharmaceutical introductions; the non-renewal or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; the ability to successfully complete the Cordis acquisition on a timely basis and if completed, to achieve the anticipated results from the Cordis acquisition; the ability to achieve the expected benefits from the AccessClosure acquisition; uncertainties due to government health care reform including federal health care reform legislation; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority; and changes in the cost of commodities such as oil-based resins, cotton, latex and diesel fuel. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This presentation reflects management's views as of May 13, 2015. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. In addition, these presentations contain Non-GAAP financial measures. Cardinal Health provides GAAP numbers, definitions and reconciling information in the Financial Appendix at the end of these presentations and on its Investors page at ir.cardinalhealth.com.
Non-GAAP diluted earnings per share from continuing operations
Please see appendix for GAAP/non-GAAP definitions and reconciling information.1 CAGR range based off of FY15 Guidance range provided on April 30, 2015 of $4.28-$4.38.2 Non-GAAP diluted earnings per share from continuing operations growth rate versus the prior year. Q3 and year-to-date (YTD) are the 3 and 9 months ending March 31, 2015, respectively.
Solutions to help standardize physician preference items
Integrated solutions for integrated health systems
Orthopedic Trauma
Emerge Medical
Cardiovascular
Negative Pressure Wound Therapy
Innovative Therapies, Inc.
AccessClosureCordis *
* Announced intent to acquire Cordis on March 2, 2015. Completion of the acquisition is subject to regulatory approval and customary closing conditions.
The sum of the components may not equal the total due to rounding.
The 5-year compound annual grow th rate for non-GAAP diluted earnings per share from continuing operations is projected to be betw een 13.8 percent and 14.4 percent, based on FY15 non-GAAP diluted
earnings per share from continuing operations guidance of $4.28 to $4.38, respectively, provided on April 30, 2015. The 4-year compound annual grow th rate for GAAP diluted earnings per share from continuing
operations for FY10 to FY14 w as 20.1 percent.
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
Fiscal Year 2014
Operating Earnings Before Provision Earnings Earnings from Diluted EPS Diluted EPS
Earnings Income Taxes for from Continuing from from Continuing
Operating Grow th and Discontinued Income Continuing Operations Continuing Operations
We present non-GAAP operating earnings and non-GAAP diluted earnings per share from continuing operations (and presentations derived from these f inancial measures, including per
share calculations) on a forw ard-looking basis. The most directly comparable forw ard-looking GAAP measures are operating earnings and diluted earnings per share from continuing
operations. We are unable to provide a quantitative reconciliation of these forw ard-looking non-GAAP measures to the most directly comparable forw ard-looking GAAP measures because
w e cannot reliably forecast restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, litigation
(recoveries)/charges, net and LIFO charges/(credits), w hich are diff icult to predict and estimate and are primarily dependent on future events. Please note that the unavailable reconciling
items could signif icantly impact our future financial results.
We apply varying tax rates depending on the item’s nature and tax jurisdiction w here it is incurred.
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation
Fiscal Year 2012
Fiscal Year 2011
Fiscal Year 2010
The sum of the components may not equal the total due to rounding.
1
2
3
4
5
6
7
8
Charges related to the make-w hole premium on the redemption of notes.
Except for compound annual grow th rates (CAGR), grow th rates in this presentation are determined by dividing the difference betw een current period results and prior period results by prior period results. CAGR is determined by subtracting one from ((the
ending value divided by the beginning value) raised to the pow er of (one divided by the number of years)).
Costs that consist primarily of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations.
The inventories of the Company's core pharmaceutical distribution facilities in the Pharmaceutical segment are valued at the low er of cost, using the LIFO method, or market. These charges or credits are included in cost of products sold, and represent
changes in the Company's LIFO inventory reserve.
In f iscal 2015, the Company began excluding last-in, f irst-out ("LIFO") inventory charges/(credits)5 from its non-GAAP earnings, for consistency w ith the presentation by some of its peers. The Company did not record any LIFO charges or credits in the f irst,
second, or third quarters of f iscal 2015 or 2014, respectively. In the second quarter of f iscal 2015, the Company excluded the loss on extinguishment of debt7 related to the early redemption of debt that occurred in December 2014 from its non-GAAP earnings.
Asset impairments and (gains)/losses from the disposal of assets not eligible to be classif ied as discontinued operations are classif ied w ithin impairments and (gain)/loss on disposal of assets w ithin the condensed consolidated statements of earnings.
Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters.
Non-GAAP Earnings from Continuing Operations: earnings from continuing operations excluding (1) restructuring and employee severance1, (2) amortization and other acquisition-related costs2, (3) impairments and (gain)/loss on disposal of assets3 , (4)
litigation (recoveries)/charges, net4, (5) LIFO charges/(credits), (6) Other Spin-Off costs6, (7) Gain on sale of CareFusion stock and (8) loss on extinguishment of debt, each net of tax.
Definitions
Non-GAAP Diluted EPS from Continuing Operations and grow th rate calculation8: non-GAAP earnings from continuing operations divided by diluted w eighted-average shares outstanding.
Programs by w hich the Company fundamentally changes its operations such as closing and consolidating facilities, moving manufacturing of a product to another location, production or business process sourcing, employee severance (including rationalizing
headcount or other signif icant changes in personnel) and realigning operations (including realignment of the management structure of a business unit in response to changing market conditions).
Costs incurred in connection w ith our Spin-Off of CareFusion w hich are included in distribution, selling, general and administrative expenses.
Cardinal Health, Inc. and Subsidiaries
Use of Non-GAAP Measures
This presentation contains f inancial measures that are not calculated in accordance w ith U.S. generally accepted accounting principles (“GAAP”). In general, the measures exclude items and charges that (i) management does not believe reflect Cardinal
Health, Inc.'s (the "Company") core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods w ithout predictable trends. Management uses these non-GAAP
financial measures internally to evaluate the Company’s performance, evaluate the balance sheet, engage in f inancial and operational planning and determine incentive compensation.
Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its f inancial and operating results and in comparing the Company’s performance to that of its
competitors. How ever, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
The non-GAAPfinancial measures disclosed by the Company should not be considered a substitute for, or superior to, f inancial measures calculated in accordance w ith GAAP, and the financial results calculated in accordance w ith GAAP and reconciliations
to those f inancial statements set forth above should be carefully evaluated.